Cite

    Shreyaskumar Patel et al.. “Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.” Cancer, vol. 125, no. 15, 2019, pp. 2610–2620. http://access.bl.uk/ark:/81055/vdc_100086851684.0x00005a